share_log

Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon

Benzinga ·  May 2 07:18

Use of proceeds to fund working capital needs stemming from Novocure's anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure's convertible notes

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment